Genetic Variants Associated with Methotrexate Efficacy and Toxicity in Early Rheumatoid Arthritis: Results from the Treatment of Early Aggressive Rheumatoid Arthritis Trial

Methotrexate (MTX) has emerged as first-line therapy for early moderate to severe rheumatoid arthritis (RA), but individual variation in treatment response remains unexplained. We tested the associations between 863 known pharmacogenetic variants and MTX response in 471 TEAR Trial participants with...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Aslibekyan, Stella, Brown, Elizabeth E., Reynolds, Richard J., Redden, David T., Morgan, Sarah, Baggott, Joseph, Sha, Jin, Moreland, Larry W., O’Dell, James R., Curtis, Jeffrey R., Mikuls, Ted R., Bridges, S. Louis, Arnett, Donna K.
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3701736/
https://ncbi.nlm.nih.gov/pubmed/23545897
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/tpj.2013.11
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars